Eli Lilly and Company (LLY)
Are You Looking for a Top Momentum Pick? Why Eli Lilly (LLY) is a Great Choice
Does Eli Lilly (LLY) have what it takes to be a top stock pick for momentum investors? Let's find out.
This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Rank.
Eli Lilly (LLY) Stock Drops Despite Market Gains: Important Facts to Note
Eli Lilly (LLY) reached $1 at the closing of the latest trading day, reflecting a -3.6% change compared to its last close.
3 Reasons Why Lilly (LLY) Is a Great Growth Stock
Lilly (LLY) possesses solid growth attributes, which could help it handily outperform the market.
3 Top Ranked Stocks to Buy for 2026 (LLY, WFRD, PGY)
Eli Lilly, Pagaya Technologies Ltd. and Weatherford International stocks all boast numerous bullish tailwinds heading into this new year.
Wall Street Analysts Think Lilly (LLY) Is a Good Investment: Is It?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Why Eli Lilly Is the Unexpected Must-Buy Dividend Powerhouse to Own in 2026
Dividend growth investing builds long-term wealth for retirement by focusing on companies that consistently increase payouts.
Eli Lilly's New Drug Data Sets Up a High-Stakes 2026
Since early August, the world's most valuable pharmaceutical stock, Eli Lilly and Company NYSE: LLY, has put on a stellar performance. After tanking 14% on Aug. 7 due to poor clinical trial results, shares have gained a whopping 71% year-to-date.
Focus: Lilly, Novo lock horns in India's obesity drug race
Global pharma giants Eli Lilly and Novo Nordisk are scrambling to cement their lead in India's booming obesity drug market before cheaper generic versions hit shelves in March next year.
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Eli Lilly's stock has crushed Nvidia's in recent weeks. What history has to say about that.
“History suggests Nvidia should modestly beat Eli Lilly over the next roughly two months,” notes a DataTrek analyst — but there are some caveats
Healthy Returns: 2026 will be the year of obesity pills from Novo Nordisk, Eli Lilly
2026 is likely the year that two new oral weight loss drugs from Novo Nordisk and Eli Lilly will reach patients in the U.S.
